Literature DB >> 2706734

Effect of cyclosporin A on daunorubicin accumulation in multidrug-resistant P388 leukemia cells measured by real-time flow cytometry.

K Nooter1, R Oostrum, R Jonker, H van Dekken, W Stokdijk, G van den Engh.   

Abstract

We investigated the mode of action of cyclosporin A (Cy-A) as a modifier of multidrug resistance in P388 mouse leukemia cells. A fluorescence-activated flow cytometer (FCM) was modified with a flow-through cuvette to allow continuous on-line monitoring of daunorubicin uptake in vitro. The addition of Cy-A to multidrug-resistant P388/R cells at steady-state daunorubicin uptake, led to a dose-dependent increase in cellular daunorubicin accumulation, as measured by FCM and high-performance liquid chromatography (HPLC). A linear relationship was found between the daunorubicin concentration in the incubation medium and the Cy-A concentration required for optimal stimulation of cellular anthracycline accumulation. The results of a cytotoxicity assay indicated that Cy-A completely restored the chemosensitivity of the P388/R cells. Intracellular Cy-A measurements in P388/S and P388/R cells showed that P388/R cells accumulated significantly less Cy-A than P388/S cells. Relatively high daunorubicin concentrations could not restore that accumulation defect. These results suggest that Cy-A promotes cellular anthracycline accumulation by competing for an outward drug-transport system that operates in multidrug-resistant cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2706734     DOI: 10.1007/BF00292407

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  24 in total

1.  Decreased retention of actinomycin D as the basis for cross-resistance in anthracycline-resistant sublines of P388 leukemia.

Authors:  M Inaba; R K Johnson
Journal:  Cancer Res       Date:  1977-12       Impact factor: 12.701

2.  Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells.

Authors:  K Dano
Journal:  Biochim Biophys Acta       Date:  1973-10-25

3.  Resistance and cross-resistance of cultured leukemia P388 cells to vincristine, adriamycin, adriamycin analogs, and actinomycin D.

Authors:  L J Wilkoff; E A Dulmadge
Journal:  J Natl Cancer Inst       Date:  1978-12       Impact factor: 13.506

4.  Comparative studies of the uptake of daunorubicin in sensitive and resistant P388 cell lines by flow cytometry and biochemical extraction procedures.

Authors:  A T McGown; T H Ward; B W Fox
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers.

Authors:  T Tsuruo; H Iida; M Nojiri; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

6.  Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells.

Authors:  T Skovsgaard
Journal:  Cancer Res       Date:  1978-12       Impact factor: 12.701

7.  Multidrug resistance of DNA-mediated transformants is linked to transfer of the human mdr1 gene.

Authors:  D W Shen; A Fojo; I B Roninson; J E Chin; R Soffir; I Pastan; M M Gottesman
Journal:  Mol Cell Biol       Date:  1986-11       Impact factor: 4.272

8.  Light scattering properties of murine hemopoietic cells.

Authors:  J W Visser; G J van den Engh; D W van Bekkum
Journal:  Blood Cells       Date:  1980

9.  Tissue distribution and myelotoxicity of daunomycin in the rat: rapid bolus injection vs continuous infusion.

Authors:  K Nooter; P Sonneveld; A Martens; A Hagenbeek; F Schultz
Journal:  Eur J Cancer Clin Oncol       Date:  1986-07

10.  Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

View more
  16 in total

Review 1.  P glycoprotein in human immunodeficiency virus type 1 infection and therapy.

Authors:  Sanjay U C Sankatsing; Jos H Beijnen; Alfred H Schinkel; Joep M A Lange; Jan M Prins
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 2.  The cyclosporins.

Authors:  Z Rehácek
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

3.  Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate.

Authors:  Olga V Leontieva; Maria N Preobrazhenskaya; Ralph J Bernacki
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

Review 4.  Multidrug resistance (MDR) genes in haematological malignancies.

Authors:  K Nooter; P Sonneveld
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 5.  Development of multidrug-resistance convertors: sense or nonsense?

Authors:  L van Zuylen; K Nooter; A Sparreboom; J Verweij
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

6.  Modulation of drug cytotoxicity in wild-type and multidrug-resistant tumor cells by stereoisomeric series of C-20'-vinblastine congeners that lack antimicrotubule activity.

Authors:  L S Borman; W G Bornmann; M E Kuehne
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 7.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

8.  Reversal effect of itraconazole on adriamycin and etoposide resistance in human leukemia cells.

Authors:  M Kurosawa; M Okabe; N Hara; K Kawamura; S Suzuki; K Sakurada; M Asaka
Journal:  Ann Hematol       Date:  1996-01       Impact factor: 3.673

9.  Cyclosporin A and verapamil have different effects on energy metabolism in multidrug-resistant tumour cells.

Authors:  H J Broxterman; H M Pinedo; G J Schuurhuis; J Lankelma
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

10.  A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance.

Authors:  J Verweij; H Herweijer; R Oosterom; M E van der Burg; A S Planting; C Seynaeve; G Stoter; K Nooter
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.